Palopegteriparatide in APS-1: Serial Cases Supporting Reduced-Dose Initiation

Palopegteriparatide (Yorvipath), a long-acting parathyroid hormone (PTH) 1–34 prodrug approved for adults with chronic hypoparathyroidism, has a recommended starting dose of 18 mcg once daily. This regimen was established predominantly in patients with postsurgical hypoparathyroidism. Evidence in autoimmune polyendocrine syndrome type 1 (APS-1)-associated hypoparathyroidism is limited to two participants in the pivotal phase 3 trial. We describe our single-centre experience with initiating palopegteriparatide in four adults with APS-1-associated hypoparathyroidism. The first two patients started palopegteriparatide at the label-recommended dose of 18 mcg once daily and developed severe hypercalcaemia within 7 days, with peak albumin-adjusted calcium of 3.60 and 3.19 mmol/L, respectively. Both were asymptomatic, and hypercalcaemia was detected by biochemical monitoring. Treatment was discontinued, and aggressive inpatient hydration and gradual re-titration were required before serum calcium stabilized. Given this experience, the subsequent two patients were initiated at a reduced dose of 9 mcg once daily. Neither developed hypercalcaemia, and both reached and maintained albumin-adjusted calcium within the reference range while discontinuing conventional supplementation. Higher pre-treatment conventional-therapy requirements, differing baseline calcium and renal function, and consecutive treatment limit attribution of these responses to the starting dose alone. These hypothesis-generating observations suggest that patients with APS-1 may benefit from a lower starting dose, together with structured early calcium monitoring, timely adjustment of conventional therapy and clear communication with patients throughout titration and maintenance.

Authors

Institutions

Publication Details

Journal
European Journal of Endocrinology
Published
2026-11-21
DOI
https://doi.org/10.1093/ejendo/lvag225
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Palopegteriparatide in APS-1: Serial Cases Supporting Reduced-Dose Initiation

Andrej Janež, Tomaž Kocjan, Rok Herman, Mojca Jensterle et al.
European Journal of Endocrinology
Parathyroid Disorders and Treatments
article

Palopegteriparatide in APS-1: Serial Cases Supporting Reduced-Dose Initiation

Andrej Janež, Tomaž Kocjan, Rok Herman, Mojca Jensterle, Andrijana Koceva
article en

Abstract

Palopegteriparatide (Yorvipath), a long-acting parathyroid hormone (PTH) 1–34 prodrug approved for adults with chronic hypoparathyroidism, has a recommended starting dose of 18 mcg once daily. This regimen was established predominantly in patients with postsurgical hypoparathyroidism. Evidence in autoimmune polyendocrine syndrome type 1 (APS-1)-associated hypoparathyroidism is limited to two participants in the pivotal phase 3 trial. We describe our single-centre experience with initiating palopegteriparatide in four adults with APS-1-associated hypoparathyroidism. The first two patients started palopegteriparatide at the label-recommended dose of 18 mcg once daily and developed severe hypercalcaemia within 7 days, with peak albumin-adjusted calcium of 3.60 and 3.19 mmol/L, respectively. Both were asymptomatic, and hypercalcaemia was detected by biochemical monitoring. Treatment was discontinued, and aggressive inpatient hydration and gradual re-titration were required before serum calcium stabilized. Given this experience, the subsequent two patients were initiated at a reduced dose of 9 mcg once daily. Neither developed hypercalcaemia, and both reached and maintained albumin-adjusted calcium within the reference range while discontinuing conventional supplementation. Higher pre-treatment conventional-therapy requirements, differing baseline calcium and renal function, and consecutive treatment limit attribution of these responses to the starting dose alone. These hypothesis-generating observations suggest that patients with APS-1 may benefit from a lower starting dose, together with structured early calcium monitoring, timely adjustment of conventional therapy and clear communication with patients throughout titration and maintenance.

European Journal of Endocrinology
University of Ljubljana (SI), Ljubljana University Medical Centre (SI), University of Maribor (SI), University Clinical Centre Maribor (SI)
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon